EOLS - Evolus, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
17.05
+0.27 (+1.61%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close16.78
Open16.74
Bid17.05 x 900
Ask17.09 x 800
Day's Range16.72 - 17.20
52 Week Range10.22 - 30.25
Volume227,403
Avg. Volume498,033
Market Cap467.588M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    Evolus Announces Successful Completion of the Jeuveau® Experience Treatment (J.E.T) Program

    Evolus, Inc. (EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the company has successfully completed the J.E.T. Program and achieved the number three unit share position for Jeuveau® in the United States. Visit us at: www.evolus.com.

  • GlobeNewswire

    Evolus to Participate in Two Upcoming Investor Conferences

    NEWPORT BEACH, Calif., Aug. 22, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.

  • GlobeNewswire

    Evolus Reports Second Quarter 2019 Financial Results

    Launched Jeuveau® in the United States on May 15 Jeuveau® Experience Treatment (J.E.T.) Program Exceeds Expectations Generated $2.3 Million in Jeuveau® Net Revenue in Q2 2019.

  • ACCESSWIRE

    Evolus, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 12, 2019 / Evolus, Inc. (NASDAQ: EOLS ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 12, 2019 at 8:00 AM Eastern ...

  • GlobeNewswire

    Evolus to Report Second Quarter 2019 Financial Results and Provide a Business Update on Monday, August 12, 2019

    NEWPORT BEACH, Calif., Aug. 01, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.

  • GlobeNewswire

    Evolus Expands Board of Directors with Appointment of Independent Directors Peter Farrell, Ph.D. and Karah Parschauer, J.D.

    NEWPORT BEACH, Calif., July 15, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.

  • GlobeNewswire

    Evolus Provides Update on Nuceiva™ Marketing Authorization Application in Europe

    Evolus, Inc. (EOLS) today provided an update on the marketing authorization application (MAA) for Nuceiva™ in Europe that may result in the European Commission (EC) extending its final decision on approval beyond the 90 days previously stated by the company. Evolus was informed by the EMA that the EC has requested supplementary information from the EMA/CHMP as part of their review of the Nuceiva™ MAA.  The EC has the ability to delay its standard timeline if additional information is requested of the EMA/CHMP during its decision-making process.

  • GlobeNewswire

    Evolus Accelerates Next Phase of U.S. Launch of Jeuveau™ with ‘#NEWTOX NOW’ Consumer Conversion Program

    Evolus, Inc. (EOLS) today announced the launch of the ‘#NEWTOX NOW’ consumer conversion program following the rapid adoption of the company’s Jeuveau™ Experience Treatment (J.E.T.) program.  Jeuveau™ (prabotulinumtoxinA-xvfs) was introduced to the U.S. market on May 15 and is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines (frown lines between the eyes) in adults.

  • GlobeNewswire

    Evolus to Participate in Three Upcoming Investor Conferences

    NEWPORT BEACH, Calif., May 28, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.

  • ALPHAEON Corporation to Pay Off $88 million of Outstanding Third-Party Debt
    PR Newswire

    ALPHAEON Corporation to Pay Off $88 million of Outstanding Third-Party Debt

    NEWPORT BEACH, Calif., May 21, 2019 /PRNewswire/ -- ALPHAEON Corporation ("ALPHAEON"), announced today that it has completed the sale of 4.0 million shares of common stock in Evolus, Inc. (EOLS) ("Evolus"). ALPHAEON intends to use the net proceeds from this offering to pay off a majority of its $88 million in third-party debt obligations, which are due in June 2019. In lieu of cash, certain of the note holders have elected to convert part of the outstanding portions of their notes into approximately 1.3 million Evolus shares.

  • ALPHAEON Corporation sells 4 million shares in Evolus Inc.
    PR Newswire

    ALPHAEON Corporation sells 4 million shares in Evolus Inc.

    NEWPORT BEACH, Calif., May 15, 2019 /PRNewswire/ -- ALPHAEON Corporation announced today that it has agreed to sell approximately 4.0 million shares of common stock in Evolus, Inc. (EOLS) in an underwritten public offering with Morgan Stanley acting as sole underwriter for the offering. No shares will be sold by Evolus in the offering nor will any of the sale proceeds go to Evolus. ALPHAEON has also granted Morgan Stanley a 30-day option to purchase up to 600,000 additional shares of Evolus common stock. The primary use of proceeds will be to pay down ALPHAEON's outstanding secured debt obligations. The offering is being made pursuant to an effective shelf registration statement on Form S-3 that was previously filed by Evolus with the SEC. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there by any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

  • GlobeNewswire

    Evolus Announces First Shipment of Jeuveau™ (prabotulinumtoxinA-xvfs) to Customers in the United States

    Evolus, Inc. (EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that with the U.S. launch of Jeuveau™ (prabotulinumtoxinA-xvfs), there’s a #NEWTOX on the market. Jeuveau™ was approved by U.S. Food and Drug Administration (FDA) in February 2019 for the temporary improvement in the appearance of moderate to severe glabellar lines (frown lines between the eyes) in adults and is the first neurotoxin in the U.S. developed with a specific focus in aesthetics. Evolus is planning to launch the Jeuveau™ Experience Treatment (J.E.T.) through approximately 3,000 accounts nationwide.

  • GlobeNewswire

    Evolus Reports First Quarter 2019 Financial Results

    NEWPORT BEACH, Calif., April 30, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.

  • GlobeNewswire

    Evolus Receives Positive CHMP Opinion for Nuceiva™ in the European Union

    Evolus, Inc. (EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the Nuceiva™ marketing authorization application. The CHMP opinion is a scientific recommendation for marketing authorization to the European Commission, which will now review the recommendation and deliver its final decision on the Company’s marketing authorization application.

  • GlobeNewswire

    Evolus to Release First Quarter 2019 Financial Results and Provide a Business Update on Tuesday, April 30, 2019

    IRVINE, Calif., April 24, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.

  • GlobeNewswire

    Evolus Announces Publication of Largest Aesthetic Head-to-Head Pivotal Trial Comparing Jeuveau™ and BOTOX® in Aesthetic Surgery Journal

    Evolus, Inc. (EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the publication of the European and Canadian Phase III head-to-head pivotal trial results in the April issue of Aesthetic Surgery Journal. “We are pleased that these data were accepted and published in the Aesthetic Surgery Journal, which is added validation of the rigor of the study,” said Rui Avelar, MD, Chief Medical Officer and Head of Research & Development. “The results of this study are compelling and reinforce the clinical performance of Jeuveau™, which is the first 900 kDa product to enter the U.S. market in nearly 30 years,” said David Moatazedi, President and Chief Executive Officer.

  • GlobeNewswire

    Evolus Provides Regulatory Update on Nuceiva™ in the European Union

    Nuceiva™ (branded Jeuveau™ in the United States) is being evaluated by the EMA for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the above facial lines has an important psychological impact in adults below 65 years of age. “We are actively addressing the CHMP’s final few questions in accordance with their timelines, which will enable them to adopt their formal opinion on our MAA during the April Committee meeting,” said Rui Avelar, MD, Chief Medical Officer and Head of Research & Development at Evolus, Inc.  “In the second quarter, in addition to an opinion in Europe, we look forward to publishing the largest head-to-head aesthetic pivotal trial of our neurotoxin versus BOTOX®, which was conducted in Europe and Canada.

  • GlobeNewswire

    Evolus Announces Publication of U.S. Phase III Pivotal Trial Results for Jeuveau™ in Dermatologic Surgery

    Evolus, Inc. (EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the publication of the U.S. Phase III pivotal trial results for Jeuveau™ in Dermatologic Surgery.  The article titled, “Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results from 2 Identical Phase III Studies”, is now available on the Journal’s Website and will be printed in the March 2019 issue. “As a principal investigator in EV-001 and EV-002, and first author on the paper, I am confident in the robustness of these results.

  • GlobeNewswire

    Evolus Reports Fourth Quarter and Full Year 2018 Results

    Received U.S. FDA Approval of Jeuveau™ on February 1, 2019 Majority of Sales Force Hired with Launch Planned in the Coming Weeks Hosting Investor & Analyst Day on May 8th,.

  • GlobeNewswire

    Evolus Secures $100 Million Senior Debt Facility with Oxford Finance LLC

    NEWPORT BEACH, Calif., March 18, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.

  • GlobeNewswire

    Evolus to Release Fourth Quarter and Full Year 2018 Financial Results and Provide a Business Update on Monday, March 18, 2019

    IRVINE, Calif., March 15, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.

  • GlobeNewswire

    Evolus Appoints Crystal Muilenburg as Vice President Corporate Communications & Public Relations

    NEWPORT BEACH, Calif., Feb. 27, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on delivering breakthrough products, today announced the appointment.

  • GlobeNewswire

    Evolus to Hold Conference Call Following Jeuveau™ FDA Approval

    NEWPORT BEACH, Calif., Feb. 04, 2019 -- Evolus, Inc. (NASDAQ: EOLS), today announced that members of management will host a conference call today, February 4th, 2019, at 8:00.

  • GlobeNewswire

    Evolus Receives FDA Approval for Jeuveau™ prabotulinumtoxinA-xvfs for Injection

    Evolus, Inc. (EOLS) today announced that the U.S. Food and Drug Administration (“FDA”) has approved its lead product, Jeuveau™, for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. David Moatazedi, President and Chief Executive Officer of Evolus, stated, “Evolus is the first company in nearly a decade to enter the fast-growing U.S. aesthetic neurotoxin market.